Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82,571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.
Wynne CJ, Ellis-Pegler RB, Waaka DS, Schwabe C, Lehle M, Heinzmann D, Mangat R, Li C, Dick AE, Cranshaw NA, Lum BL. Wynne CJ, et al. Among authors: li c. Cancer Chemother Pharmacol. 2013 Nov;72(5):1079-87. doi: 10.1007/s00280-013-2273-z. Epub 2013 Sep 22. Cancer Chemother Pharmacol. 2013. PMID: 24057039 Clinical Trial.
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL, Hillenbach C, Li J, Li H, Wada RD, Visich J, Li C, Heinzmann D, Jin JY, Lum BL. Quartino AL, et al. Among authors: li c, li j, li h. Cancer Chemother Pharmacol. 2016 Jan;77(1):77-88. doi: 10.1007/s00280-015-2922-5. Epub 2015 Dec 8. Cancer Chemother Pharmacol. 2016. PMID: 26645407 Free PMC article. Clinical Trial.
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Wang B, Deng R, Hennig S, Badovinac Crnjevic T, Kaewphluk M, Kågedal M, Quartino AL, Girish S, Li C, Kirschbrown WP. Wang B, et al. Among authors: li c. Cancer Chemother Pharmacol. 2021 Sep;88(3):499-512. doi: 10.1007/s00280-021-04296-0. Epub 2021 Jun 9. Cancer Chemother Pharmacol. 2021. PMID: 34106303 Free PMC article. Clinical Trial.
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D, Li C, Riggs M, Polhamus D, French J, Agarwal P, Chen SC, Vadhavkar S, Patre M, Strasak A, Quartino A, Jin JY, Girish S. Lu D, et al. Among authors: li c. Cancer Chemother Pharmacol. 2019 Jul;84(1):175-185. doi: 10.1007/s00280-019-03852-z. Epub 2019 May 17. Cancer Chemother Pharmacol. 2019. PMID: 31102024 Clinical Trial.
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Li C, Wang B, Chen SC, Wada R, Lu D, Wang X, Polhamus D, French J, Vadhavkar S, Strasak A, Smitt M, Joshi A, Samant M, Quartino A, Jin J, Girish S. Li C, et al. Cancer Chemother Pharmacol. 2017 Dec;80(6):1079-1090. doi: 10.1007/s00280-017-3440-4. Epub 2017 Oct 11. Cancer Chemother Pharmacol. 2017. PMID: 29022084 Clinical Trial.
82,571 results
You have reached the last available page of results. Please see the User Guide for more information.